°£Æí°áÁ¦, ½Å¿ëÄ«µå û±¸ÇÒÀÎ
ÀÎÅÍÆÄÅ© ·Ôµ¥Ä«µå 5% (47,500¿ø)
(ÃÖ´ëÇÒÀÎ 10¸¸¿ø / Àü¿ù½ÇÀû 40¸¸¿ø)
ºÏÇǴϾð ·Ôµ¥Ä«µå 30% (35,000¿ø)
(ÃÖ´ëÇÒÀÎ 3¸¸¿ø / 3¸¸¿ø ÀÌ»ó °áÁ¦)
NH¼îÇÎ&ÀÎÅÍÆÄÅ©Ä«µå 20% (40,000¿ø)
(ÃÖ´ëÇÒÀÎ 4¸¸¿ø / 2¸¸¿ø ÀÌ»ó °áÁ¦)
Close

¾à¹°³ª¹« : ¾à¹° ³»ºñ°ÔÀ̼Ç, ³ª¹«¸¦ º¸¸é ¾à¹°ÀÌ º¸ÀδÙ[¾çÀå]

¼Òµæ°øÁ¦

2013³â 9¿ù 9ÀÏ ÀÌÈÄ ´©Àû¼öÄ¡ÀÔ´Ï´Ù.

ÆǸÅÁö¼ö 75
?
ÆǸÅÁö¼ö¶õ?
»çÀÌÆ®ÀÇ ÆǸŷ®¿¡ ±â¹ÝÇÏ¿© ÆǸŷ® ÃßÀ̸¦ ¹Ý¿µÇÑ ÀÎÅÍÆÄÅ© µµ¼­¿¡¼­ÀÇ µ¶¸³ÀûÀÎ ÆǸŠÁö¼öÀÔ´Ï´Ù. ÇöÀç °¡Àå Àß Æȸ®´Â »óÇ°¿¡ °¡ÁßÄ¡¸¦ µÎ¾ú±â ¶§¹®¿¡ ½ÇÁ¦ ´©Àû ÆǸŷ®°ú´Â ´Ù¼Ò Â÷ÀÌ°¡ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. ÆǸŷ® ¿Ü¿¡µµ ´Ù¾çÇÑ °¡ÁßÄ¡·Î ±¸¼ºµÇ¾î ÃÖ±ÙÀÇ À̽´µµ¼­ È®Àνà À¯¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇØ´ç Áö¼ö´Â ¸ÅÀÏ °»½ÅµË´Ï´Ù.
Close
°øÀ¯Çϱâ
Á¤°¡

50,000¿ø

  • 50,000¿ø

    1,500P (3%Àû¸³)

ÇÒÀÎÇýÅÃ
Àû¸³ÇýÅÃ
  • S-Point Àû¸³Àº ¸¶ÀÌÆäÀÌÁö¿¡¼­ Á÷Á¢ ±¸¸ÅÈ®Á¤ÇϽŠ°æ¿ì¸¸ Àû¸³ µË´Ï´Ù.
Ãß°¡ÇýÅÃ
¹è¼ÛÁ¤º¸
  • 4/1(¿ù) À̳» ¹ß¼Û ¿¹Á¤  (¼­¿ï½Ã °­³²±¸ »ï¼º·Î 512)
  • ¹«·á¹è¼Û
ÁÖ¹®¼ö·®
°¨¼Ò Áõ°¡
  • À̺¥Æ®/±âȹÀü

  • ¿¬°üµµ¼­

  • »óÇ°±Ç

AD

Ã¥¼Ò°³

¾à¹° ¸í¸íÀÇ ¿ø¸®¿Í ±âÁØ¿¡ µû¶ó 11°³ÀÇ ¡®¾à¹°³ª¹«¡¯ Å׸¶ ½£À¸·Î ±¸¼ºÇÏ¿´´Ù. ¸Å ½£¸¶´Ù ¸ñÂ÷¿Í ´ëÇ¥Àû ¾à¹°ÀÇ ÀÛ¿ë ºÎÀ§¿Í ±âÀüÀ» 56ÀåÀÇ ±×¸²À̳ª Ç¥·Î ÀÌÁ¤Ç¥¸¦ Á¦½ÃÇÏ¿´´Ù. ¾à¹°³ª¹«ÀÇ ÁÙ±â¿Í ÀÙÀÚ·ç¿¡ ´ëºÐ·ù ºÎÅÍ Áߺзù, ¼ÒºÐ·ù¸¦ Ç¥±âÇÏ¿´°í, ÇлýµéÀÌ ²À ¾Ë¾Æ¾ß ÇÒ ¿øÇü(prototype) ¾à¹° ¶Ç´Â ´ëÇ¥ ¾à¹°À» »ö»óÀ¸·Î ±¸ºÐÇÏ¿´´Ù. ¶ÇÇÑ, Á¹¾÷»ýµé°ú Á¦¾à»ç¿¡¼­ ¾Ë¾Æ¾ß ÇÒ ÇöÀç ½ÃÆÇ ÁßÀÎ ¾à¹°°ú ½ÃÆǵÇÁö ¾Ê°í ÀÖ´Â ¾à¹°À» »ö»óÀ¸·Î ±¸ºÐÇÏ¿´´Ù.

ÃâÆÇ»ç ¼­Æò

¾à¸®ÇÐÀº ±âÃÊ¿Í ÀÓ»óÀÇ ±³·® ¿ªÇÒÀ» ÇÏ´Â Áß¿äÇÑ °ú¸ñÀÓ¿¡µµ ºÒ±¸ÇÏ°í ¼ö¸¹Àº Á¾·ùÀÇ ¾à¹° ¶§¹®¿¡ ¾î·Æ°í Àç¹Ì¾ø´Â °ú¸ñÀ¸·Î Àνĵǰí ÀÖ´Ù. ¾à¹°ÀÇ ÀÛ¿ë±âÀüÀ» Àß ÀÌÇØÇÏ°í, ü°èÀûÀ¸·Î ºÐ·ùÇÏ°í °øºÎÇÒ ¼ö ÀÖ°Ô ÇÒ °ÍÀΰ¡¿¡ ´ëÇÑ °í¹ÎÀ¸·ÎºÎÅÍ Ãâ¹ßÇÏ¿© ´Ù¾çÇÑ ¿ø¸®¿Í ±âÁØ¿¡ µû¶ó ¸ðµç ¾à¹°À» ºÐ·ùÇÑ 11°³ÀÇ ¡®¾à¹°³ª¹«¡¯ Å׸¶ ½£ÀÌ Åº»ýÇÏ¿´´Ù.

¡®¾à¹°³ª¹«¡¯ ½£ ¾Õ¿¡ ¼¼¿öÁø ÀÌÁ¤Ç¥(¸ñÂ÷¿Í ¼­·Ð)¸¦ º¸°í ¾à¹° Å׸¶º° ½£¿¡ µé¾î°¡º¸¸é, ´ëºÐ·ù ¾à¹°³ª¹«¸¦ ¸¸³ª°Ô µÇ°í, Áٱ⿡ Ç¥±âµÈ Áߺзù¿Í ÀÙÀÚ·ç µî¿¡ Ç¥±âµÈ ¼ÒºÐ·ù¸¦ º¼ ¼ö ÀÖ´Ù. ³ª¹µÀÙ¸¸ º¸¾Æµµ ¿øÇü(prototype)¾à¹° ¶Ç´Â ´ëÇ¥ ¾à¹°(³ë¶õ»ö), ÇöÀç ½ÃÆÇ ÁßÀÎ ¾à¹°(³ì»ö), ½ÃÆǵÇÁö ¾Ê°í ÀÖ´Â ¾à¹°(¿¬µÎ»ö), »ý»ê ÁߴܵǾú°Å³ª ½ÃÀå¿¡¼­ ö¼öµÈ ¾à¹°(³«¿±»ö)À» ±¸º°ÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿´´Ù. ÁÂÃø¿¡´Â ÀϹݸí(¿¹, ¼ººÐ¸í ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ), ¿ìÃø¿¡´Â »óÇ°¸í(¿¹, ºê·£µå¸í ŸÀÌ·¹³î)À» ´ëĪÀ¸·Î ¹èÄ¡ÇÏ¿© °Å¿ï À̹ÌÁö·Î º¼ ¼ö ÀÖ°Ô ÇÏ¿´´Ù. ¹Ì±¹¿¡¼­ Çã°¡µÈ Á¦³×¸¯ ¾à¹°(ÁÖ·Î ¼öÀÍÀÌ ¿¹»óµÉ ¶§ »ý»êÇÏ´Â °¡°ÝÀÌ Àú·ÅÇÑ º¹Á¦¾à)Àº ±½Àº ±Û¾¾·Î Ç¥±âÇÏ¿´°í, ½ÃÀå¿¡¼­ ö¼öµÈ °æ¿ì ö¼ö¿¬µµ, ÇØ´ç ±¹°¡(°³¼ö)¿Í ö¼ö ÀÌÀ¯¸¦ Ç¥±âÇÏ¿´´Ù.

Á¦Ç°Àº ¿À¸®Áö³¯ Á¦Ç° ¹× ¼±ÅÃÀÇ ÆøÀÌ ³ÐÀº ´ëÇ¥ÀûÀÎ ºê·£µå¸¦ ³ª¹µÀÙ¿¡ Ç¥±âÇÏ¿´À¸¸ç, ³ª¹µÀÙ ¾Æ·¡¿¡´Â Á¦Çü, °³¼ö ¹× Á¦Á¶È¸»ç¸¦ Ç¥±âÇÏ¿´´Ù. ¾à¹°³ª¹«´Â ´Ü¼øÇѾ๰ÀÇ ºÐ·ù¿Í Ç¥±â¿¡ ±×Ä¡Áö ¾Ê°í ¾à¹°ÀÇ ¼±Åà ±âÁØÀÌ µÉ ¼ö ÀÖ´Â Á¤º¸¿Í ƯÈ÷ ¿ì·ÁµÇ´Â ºÎÀÛ¿ë µî Ãß°¡ Á¤º¸´Â °¢ÁÖ¿¡ ¹®Çå°ú ÇÔ²² Ç¥±âÇÏ¿´´Ù. ¾à¹° Á¤º¸´Â ³×À̹ö, ±¸±Û, À§Å°Çǵð¾Æ, drugs.com, Å´½º¿Â¶óÀÎ(kimsonline.co.kr) ¹× Æà¸Þµå(PubMed)·ÎºÎÅÍ ÁÖ·Î ¾ò¾ú´Ù.

¡®¾à¹°³ª¹«¡¯´Â °ü·Ã Çаú Çлý/¿¬±¸¿ø, ÀÇ»ç/¾à»ç/°£È£»ç/¼öÀÇ»ç, ÀÇ¾à °ü·Ã ±â°ü, ȸ»ç ¹× ȯÀÚ ¶Ç´Â º¸È£ÀÚµéÀÌ ¾à¹°À» º¸´Ù ½±°Ô ÀÌÇØÇϴµ¥ ÀÖ¾î ±æ¾È³»ÀÚ°¡ µÇ´Â µµ¼­ÀÌ´Ù.

ÀÌ Ã¥ÀÇ Æ¯Â¡
¤ý ¾à¹° ¸í¸íÀÇ ¿ø¸®¿Í ±âÁØ¿¡ µû¶ó 11°³ÀÇ ¡®¾à¹°³ª¹«¡¯ Å׸¶ ½£(852p)À¸·Î ±¸¼º
¤ý ¸Å ½£¸¶´Ù ¸ñÂ÷¿Í ´ëÇ¥Àû ¾à¹°ÀÇ ÀÛ¿ë ºÎÀ§¿Í ±âÀüÀ» 56ÀåÀÇ ±×¸²À̳ª Ç¥·Î ÀÌÁ¤Ç¥¸¦ Á¦½Ã
¤ý ¾à¹°³ª¹«ÀÇ ÁÙ±â¿Í ÀÙÀÚ·ç¿¡ ´ëºÐ·ù ºÎÅÍ Áߺзù, ¼ÒºÐ·ù Ç¥±â
¤ý ÇлýµéÀÌ ²À ¾Ë¾Æ¾ß ÇÒ ¿øÇü(prototype) ¾à¹° ¶Ç´Â ´ëÇ¥ ¾à¹°À» »ö»óÀ¸·Î ±¸ºÐ
¤ý Á¹¾÷»ýµé°ú Á¦¾à»ç¿¡¼­ ¾Ë¾Æ¾ß ÇÒ ÇöÀç ½ÃÆÇ ÁßÀÎ ¾à¹°°ú ½ÃÆǵÇÁö ¾Ê°í ÀÖ´Â ¾à¹°À» »ö»óÀ¸·Î ±¸ºÐ (ö¼ö ¿¬µµ, ÇØ´ç ±¹°¡ °³¼ö¿Í ö¼ö ÀÌÀ¯ µî °¡´ÉÇÑ Á¤º¸ ±âÀÔ)
¤ý ÁÂÃø¿¡´Â ÀϹݸí(¼ººÐ¸í), ¿ìÃø¿¡´Â »óÇ°¸íÀ» ¹èÄ¡ÇÏ¿© ÁÂ¿ì °Å¿ï À̹ÌÁö·Î º¼ ¼ö ÀÖµµ·Ï Á¦ÀÛ
¤ý ÀϹݸíÀº ¾à¹°ÀÇ ¼±Åà ±âÁØÀÌ µÉ ¼ö ÀÖ´Â Á¤º¸¿Í ƯÈ÷ ¿ì·ÁµÇ´Â ºÎÀÛ¿ë µîÀº °¢ÁÖ¿¡ ¹®Çå°ú ÇÔ²² Ç¥±â
¤ý »óÇ°¸íÀº ¿À¸®Áö³¯ ¶Ç´Â ´Ù¾çÇÑ Á¦ÇüÀ» »ý»êÇϴ ȸ»ç¸¦ ³ª¹µÀÙ¿¡, °¢ÁÖ¿¡´Â Çã°¡³»¿ë ¹× ±âŸ Á¦Ç°À» Ç¥±â
¤ý ¹Ì±¹¿¡¼­ Çã°¡µÈ Á¦³×¸¯ ¾à¹°(¼öÀÍÀÌ ¿¹»óµÉ ¶§ »ý»êÇÏ´Â °¡°ÝÀÌ Àú·ÅÇÑ º¹Á¦¾à)Àº ±½Àº(bold) ±Û¾¾·Î Ç¥±â
¤ý ¼öÀÇ¿ë ¶Ç´Â ºñÇã°¡(off-label) ÀûÀÀÁõ µî Æø³ÐÀº ³»¿ë ¼ö·Ï
¤ý ÃÖ±Ù ±¹³» ó¹æ »óÀ§ 50À§ Á¦Ç°°ú ¼øÀ§º¯µ¿ ºÎ·ÏÀÚ·á Á¦½Ã

¸ñÂ÷

"ÀúÀÚÀÌ·Â iii
¸Ó¸®¸» iv
¾à¹°³ª¹« º¸´Â ¹ý vi

1. ÀÚÀ²½Å°æ°è ¾à¹° ANS drugs 2
1-1 ¾Æµå·¹³¯¸°¼º È¿´ÉÁ¦(Adrenergic agonists) 4
1-2 ¾Æµå·¹³¯¸°¼º ±æÇ×Á¦(Adrenergic antagonists) 14
1-3 °£Á¢ÀÛ¿ë ±³°¨½Å°æÈïºÐÁ¦(Indirect sympathomimetics) 24
1-4 Äݸ°¼º È¿´ÉÁ¦(Cholinergic agonists) 30
1-5 Äݸ°¼º ±æÇ×Á¦(Cholinergic antagonists) 36

2. ÁßÃ߽Űæ°è ¾à¹° CNS drugs 48
2-1 ÁøÁ¤¼ö¸éÁ¦(Sedative-hypnotics) 50
2-2 ¾ËÄÚ¿Ã ¹× °ü·Ã ¾à¹°(Alcohol and related drugs) 64
2-3 Ç×Á¤½Åº´£¨½Å°æÀÌ¿Ï)Á¦(Antipsychotics or neuroleptics) 70
2-4 Ç×ÆÄŲ½¼º´Á¦ ¹× Ç×¹«µµº´Á¦(Antiparkinson and antichorea drugs) 84
2-5 Ç״ٹ߼º°æÈ­ÁõÁ¦ ¹× Ç×·ç°Ô¸¯Á¦(Anti-MS and anti-ALS drugs) 94
2-6 Ç׿ì¿ïÁ¦, Ç×Á¶ÁõÁ¦ ¹× ±âºÐ¾ÈÁ¤Á¦(Antidepressants, antimanics and mood stabilizers) 102
2-7 Ç×Àü°£Á¦(Antiepileptics) 112
2-8 ¾ÆÆíÀ¯»ç È¿´ÉÁ¦ ¹× ±æÇ×Á¦(Opioid agonists and antagonists) 122
2-9 ³²¿ë¾à¹°(Abused drugs) 130

3. ¸¶ÃëÁ¦ ¹× °ü·Ã ¾à¹° Anesthetics and related drugs 148
3-1 ±¹¼Ò¸¶ÃëÁ¦(Local anesthetics) 150
3-2 ¸¶ÃëÀü Åõ¾à(Preanesthetic medication) 156
3-3 Àü½Å¸¶ÃëÁ¦(General anesthetics) 162
3-4 °ñ°Ý±Ù ÀÌ¿ÏÁ¦-½Å°æ±ÙÀ°Â÷´ÜÁ¦(Skeletal muscle relaxants-Neuromuscular blockers) 172
3-5 °ñ°Ý±Ù ÀÌ¿ÏÁ¦-Áø°æÁ¦(Skeletal muscle relaxants-Spasmolytics) 178

4. ½ÉÇ÷°üÁúȯ Ä¡·áÁ¦ ¹× ÀÌ´¢Á¦ CVD drugs and diuretics 186
4-1 Ç×°íÇ÷¾ÐÁ¦(Antihypertensives) 188
4-2 ½ÉºÎÀüÁõ Ä¡·áÁ¦(Drugs for heart failure) 202
4-3 Ç׺ÎÁ¤¸ÆÁ¦(Antiarrhythmics) 212
4-4 Ç×Çù½ÉÁõÁ¦(Antianginals) 220
4-5 Ç÷°üÈ®ÀåÁ¦(Vasodilators) 228
4-6 ÀÌ´¢Á¦(Diuretics) 234

5. Ç÷¾×Áúȯ Ä¡·áÁ¦ Drugs for blood diseases 252
5-1 Ç×°íÁöÇ÷ÁõÁ¦(Antihyperlipidemics) 254
5-2 Ç×Ç÷¼ÒÆÇÁ¦ ¹× Ç×ÀÀ°íÁ¦(Antiplatelets and anticoagulants) 266
5-3 Á¶Ç÷ÀÚ±ØÁ¦(Hematopoietic stimulators) 284

6. ³»ºÐºñ ¹× ´ë»ç Áúȯ Ä¡·áÁ¦ Drugs for endocrine and metabolic diseases 294
6-1 ½Ã»óÇϺΠ¹× ³úÇϼöü È£¸£¸ó(Hypothalamic and pituitary hormones) 296
6-2 °©»ó¼±Á¦ ¹× Ç×°©»ó¼±Á¦(Thyroids and antithyroids) 308
6-3 Ç×´ç´¢º´Á¦(Antidiabetics) 314
6-4 Ç׺ñ¸¸Á¦(Antiobesity drugs) 338
6-5 »À °ü·Ã ¾à¹°(Bone-related drugs) 344
6-6 ºÎ½ÅÇÇÁú ¾à¹°(Adrenal cortical drugs) 356
6-7 ¾Èµå·Î°Õ È¿´ÉÁ¦ ¹× ±æÇ×Á¦(Androgen agonists and antagonists) 366
6-8 ¿©¼º »ý½Ä°è ¾à¹°(Female reproductive drugs) 372

7. È­Çпä¹ýÁ¦ Chemotherapeutics 412
7-1 ¼¼Æ÷º® ¾ïÁ¦Á¦(Cell wall inhibitors) 414
7-2 ÇÙ»êÇÕ¼º ¾ïÁ¦Á¦(Nucleic acid synthesis inhibitors) 440
7-3 ´Ü¹éÇÕ¼º ¾ïÁ¦Á¦(Protein synthesis inhibitors) 448
7-4 Ç×°áÇÙ ¹× Ç׳ªº´Á¦(Antituberculosis and antileprotic drugs) 464
7-5 Ç×¹ÙÀÌ·¯½ºÁ¦(Antivirals) 474
7-6 Ç׿øÃæÁ¦(Antiprotozoals) 504
7-7 Ç×Áø±ÕÁ¦(Antifungals) 528
7-8 ±¸ÃæÁ¦(Anthelminthics) 538
7-9 Ç×¾ÏÁ¦(Anticancer drugs) 548

8. ¸é¿ª ¹× ¿°Áõ Áúȯ Ä¡·áÁ¦ Drugs for immune and inflammatory diseases 640
8-1 ¸é¿ª¾ïÁ¦Á¦(Immunosuppresants) 642
8-2 ¸é¿ªÁ¶ÀýÁ¦(Immunomodulators) 656
8-3 ¾ÆÀÌÄÚ»ç³ëÀ̵å È¿´ÉÁ¦ ¹× ±æÇ×Á¦(Eicosanoid agonists and antagonists) 676
8-4 Ç×·ù¸¶Æ¼½ºÁ¦(Antirheumatics) 704
8-5 Ç×ÅëdzÁ¦(Antigout drugs) 720

9. È£Èí±â ¾à¹° Respiratory drugs 734
9-1 Ç×È÷½ºÅ¸¹ÎÁ¦(Antihistamines) 736
9-2 ÁøÇØÁ¦, Á¡¾×È°¼ºÈ­Á¦ ¹× ºñÃæÇ÷ ¿ÏÈ­Á¦(Anticough, mucoactive and nasal decongestant drugs) 746
9-3 Ç×õ½ÄÁ¦(Antiasthmatics) 750

10. À§Àå°ü ¾à¹° GI drugs 776
10-1 »óºÎÀ§Àå°ü ¾à¹°(Upper GI drugs) 778
10-2 Ç×±¸ÅäÁ¦(Antiemetics) 792
10-3 ÇϺÎÀ§Àå°ü ¾à¹°(Lower GI drugs) 802

11. µ¶±Ø¹°°ú Çص¶Á¦ Toxiants and antidotes 836
11-1 ¾à¹° °ú´Ù º¹¿ë ¹× Áßµ¶ÀÇ Çص¶Á¦(Antidotes for drug overdose and poisons) 838
11-2 Áß±Ý¼Ó Å³·¹ÀÌÅÍ(Heavy metal chelators) 848

ºÎ·Ï 854
±¹³» »óÀ§ ¸ÅÃâ 50À§ ó¹æ ¾à¹°(Top 50 prescribed drugs) 856"

ÀÚ¿¬°ú °úÇÐ ºÐ¾ß¿¡¼­ ¸¹Àº ȸ¿øÀÌ ±¸¸ÅÇÑ Ã¥

    ¸®ºä

    0.0 (ÃÑ 0°Ç)

    100ÀÚÆò

    ÀÛ¼º½Ã À¯ÀÇ»çÇ×

    ÆòÁ¡
    0/100ÀÚ
    µî·ÏÇϱâ

    100ÀÚÆò

    0.0
    (ÃÑ 0°Ç)

    ÆǸÅÀÚÁ¤º¸

    • ÀÎÅÍÆÄÅ©µµ¼­¿¡ µî·ÏµÈ ¿ÀǸ¶ÄÏ »óÇ°Àº ±× ³»¿ë°ú Ã¥ÀÓÀÌ ¸ðµÎ ÆǸÅÀÚ¿¡°Ô ÀÖÀ¸¸ç, ÀÎÅÍÆÄÅ©µµ¼­´Â ÇØ´ç »óÇ°°ú ³»¿ë¿¡ ´ëÇØ Ã¥ÀÓÁöÁö ¾Ê½À´Ï´Ù.

    »óÈ£

    (ÁÖ)±³º¸¹®°í

    ´ëÇ¥ÀÚ¸í

    ¾Èº´Çö

    »ç¾÷ÀÚµî·Ï¹øÈ£

    102-81-11670

    ¿¬¶ôó

    1544-1900

    ÀüÀÚ¿ìÆíÁÖ¼Ò

    callcenter@kyobobook.co.kr

    Åë½ÅÆǸž÷½Å°í¹øÈ£

    01-0653

    ¿µ¾÷¼ÒÀçÁö

    ¼­¿ïƯº°½Ã Á¾·Î±¸ Á¾·Î 1(Á¾·Î1°¡,±³º¸ºôµù)

    ±³È¯/ȯºÒ

    ¹ÝÇ°/±³È¯ ¹æ¹ý

    ¡®¸¶ÀÌÆäÀÌÁö > Ãë¼Ò/¹ÝÇ°/±³È¯/ȯºÒ¡¯ ¿¡¼­ ½Åû ¶Ç´Â 1:1 ¹®ÀÇ °Ô½ÃÆÇ ¹× °í°´¼¾ÅÍ(1577-2555)¿¡¼­ ½Åû °¡´É

    ¹ÝÇ°/±³È¯°¡´É ±â°£

    º¯½É ¹ÝÇ°ÀÇ °æ¿ì Ãâ°í¿Ï·á ÈÄ 6ÀÏ(¿µ¾÷ÀÏ ±âÁØ) À̳»±îÁö¸¸ °¡´É
    ´Ü, »óÇ°ÀÇ °áÇÔ ¹× °è¾à³»¿ë°ú ´Ù¸¦ °æ¿ì ¹®Á¦Á¡ ¹ß°ß ÈÄ 30ÀÏ À̳»

    ¹ÝÇ°/±³È¯ ºñ¿ë

    º¯½É ȤÀº ±¸¸ÅÂø¿À·Î ÀÎÇÑ ¹ÝÇ°/±³È¯Àº ¹Ý¼Û·á °í°´ ºÎ´ã
    »óÇ°À̳ª ¼­ºñ½º ÀÚüÀÇ ÇÏÀÚ·Î ÀÎÇÑ ±³È¯/¹ÝÇ°Àº ¹Ý¼Û·á ÆǸÅÀÚ ºÎ´ã

    ¹ÝÇ°/±³È¯ ºÒ°¡ »çÀ¯

    ·¼ÒºñÀÚÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óÇ° µîÀÌ ¼Õ½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì
    (´ÜÁö È®ÀÎÀ» À§ÇÑ Æ÷Àå ÈѼÕÀº Á¦¿Ü)

    ·¼ÒºñÀÚÀÇ »ç¿ë, Æ÷Àå °³ºÀ¿¡ ÀÇÇØ »óÇ° µîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì
    ¿¹) È­ÀåÇ°, ½ÄÇ°, °¡ÀüÁ¦Ç°(¾Ç¼¼¼­¸® Æ÷ÇÔ) µî

    ·º¹Á¦°¡ °¡´ÉÇÑ »óÇ° µîÀÇ Æ÷ÀåÀ» ÈѼÕÇÑ °æ¿ì
    ¿¹) À½¹Ý/DVD/ºñµð¿À, ¼ÒÇÁÆ®¿þ¾î, ¸¸È­Ã¥, ÀâÁö, ¿µ»ó È­º¸Áý

    ·½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇØ ÀçÆǸŰ¡ °ï¶õÇÑ Á¤µµ·Î °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì

    ·ÀüÀÚ»ó°Å·¡ µî¿¡¼­ÀÇ ¼ÒºñÀÚº¸È£¿¡ °üÇÑ ¹ý·üÀÌ Á¤ÇÏ´Â ¼ÒºñÀÚ Ã»¾àöȸ Á¦ÇÑ ³»¿ë¿¡ ÇØ´çµÇ´Â °æ¿ì

    »óÇ° Ç°Àý

    °ø±Þ»ç(ÃâÆÇ»ç) Àç°í »çÁ¤¿¡ ÀÇÇØ Ç°Àý/Áö¿¬µÉ ¼ö ÀÖÀ½

    ¼ÒºñÀÚ ÇÇÇغ¸»ó
    ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó

    ·»óÇ°ÀÇ ºÒ·®¿¡ ÀÇÇÑ ±³È¯, A/S, ȯºÒ, Ç°Áúº¸Áõ ¹× ÇÇÇغ¸»ó µî¿¡ °üÇÑ »çÇ×Àº ¼ÒºñÀÚºÐÀïÇØ°á ±âÁØ (°øÁ¤°Å·¡À§¿øȸ °í½Ã)¿¡ ÁØÇÏ¿© 󸮵Ê

    ·´ë±Ý ȯºÒ ¹× ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó±Ý Áö±Þ Á¶°Ç, ÀýÂ÷ µîÀº ÀüÀÚ»ó°Å·¡ µî¿¡¼­ÀÇ ¼ÒºñÀÚ º¸È£¿¡ °üÇÑ ¹ý·ü¿¡ µû¶ó ó¸®ÇÔ

    (ÁÖ)KGÀ̴Ͻýº °áÁ¦´ë±Ý¿¹Ä¡¾÷ µî·Ï¹øÈ£: 02-006-00013

    (ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º´Â ȸ¿ø´ÔµéÀÇ ¾ÈÀü°Å·¡¸¦ À§ÇØ ±¸¸Å±Ý¾×, °áÁ¦¼ö´Ü¿¡ »ó°ü¾øÀÌ (ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º¸¦ ÅëÇÑ
    ¸ðµç °Å·¡¿¡ ´ëÇÏ¿© (ÁÖ)KGÀ̴Ͻýº°¡ Á¦°øÇÏ´Â ±¸¸Å¾ÈÀü¼­ºñ½º¸¦ Àû¿ëÇÏ°í ÀÖ½À´Ï´Ù.
    µî·Ï ¿©ºÎ´Â e-±ÝÀ¶¹Î¿ø¼¾ÅÍ È¨ÆäÀÌÁö(www.fcsc.kr)ÀÇ µî·Ï¡¤½Å°í>ÀüÀÚ±ÝÀ¶¾÷µî·ÏÇöȲ ¸Þ´º¿¡¼­ È®ÀÎÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù. ¼­ºñ½º °¡ÀÔ»ç½Ç È®ÀÎ

    ¹è¼Û¾È³»

    • ±³º¸¹®°í »óÇ°Àº Åùè·Î ¹è¼ÛµÇ¸ç, Ãâ°í¿Ï·á 1~2Àϳ» »óÇ°À» ¹Þ¾Æ º¸½Ç ¼ö ÀÖ½À´Ï´Ù.

    • Ãâ°í°¡´É ½Ã°£ÀÌ ¼­·Î ´Ù¸¥ »óÇ°À» ÇÔ²² ÁÖ¹®ÇÒ °æ¿ì Ãâ°í°¡´É ½Ã°£ÀÌ °¡Àå ±ä »óÇ°À» ±âÁØÀ¸·Î ¹è¼ÛµË´Ï´Ù.

    • ±ººÎ´ë, ±³µµ¼Ò µî ƯÁ¤±â°üÀº ¿ìü±¹ Åù踸 ¹è¼Û°¡´ÉÇÕ´Ï´Ù.

    • ¹è¼Ûºñ´Â ¾÷ü ¹è¼Ûºñ Á¤Ã¥¿¡ µû¸¨´Ï´Ù.

    • - µµ¼­ ±¸¸Å ½Ã 15,000¿ø ÀÌ»ó ¹«·á¹è¼Û, 15,000¿ø ¹Ì¸¸ 2,500¿ø - »óÇ°º° ¹è¼Ûºñ°¡ ÀÖ´Â °æ¿ì, »óÇ°º° ¹è¼Ûºñ Á¤Ã¥ Àû¿ë